Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

These experiments were conducted to determine 1,2-diacylglycerol (DAG) in the thoracic aorta obtained from streptozocin-induced diabetic rats because 1,2-DAG is assumed to be a second messenger associated with phosphoinositide metabolism. After preincubation for a 25-min stabilization, 1,2-DAG content in isolated thoracic aortas 4 and 8 wk after streptozocin injection was significantly decreased by 42 and 31%, respectively, compared with age-matched control rats on 10-min norepinephrine stimulation (10(-5) M). However, 4 wk of daily insulin injection after 4 wk of untreated diabetes significantly shifted 1,2-DAG toward normal levels. Analysis of its fatty acid composition showed a significant difference between control and diabetic rat aortas at both 4 and 8 wk. In particular, the percentage of arachidonate, a precursor of eicosanoids, decreased. Such alteration in the fatty acid profile in diabetic rat aortas was inhibited by insulin treatment. 1,2-DAG content in the 8-wk diabetic group was also significantly decreased by 33% compared with control in the absence of norepinephrine, whereas 1,2-DAG content was lower than in the presence of norepinephrine in both the control and diabetic groups. Cholesterol, triglyceride, and phosphatidylcholine content in diabetic rat aortas was lower than control. Lower levels of 1,2-DAG in the thoracic aorta from diabetic rats were observed in the presence and absence of norepinephrine, suggesting that a defect in 1,2-DAG production may be associated with abnormalities of vascular smooth muscle responsiveness by agonists, as described previously.
Diabetes 1991 Jul
PMID:1,2-diacylglycerol content and its fatty acid composition in thoracic aorta of diabetic rats. 206 Jul 18

Coronary heart disease is the leading cause of mortality among persons with diabetes mellitus, but the factors that account for this high coronary heart disease mortality remain unclear. In the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study, conducted from 1982 to 1984, 92 deaths from coronary heart disease were found to have occurred among 602 diabetic participants and 558 deaths from coronary heart disease were found to have occurred among 12,562 nondiabetic participants during the follow-up period (1971-1984; average follow-up, 10 years). Using proportional hazards analysis, the authors found age, male sex, severe overweight, and non-leisure-time physical inactivity to be significantly associated with coronary heart disease mortality among persons with diabetes. Age, male sex, current smoking, hypertension, and non-leisure-time physical inactivity were associated with all-cause mortality. Cholesterol showed a more complex relation to all-cause mortality. The strength of the associations between risk factors and all-cause and coronary heart disease mortality did not differ significantly among persons with and without diabetes. These results reinforce the importance of controlling coronary heart disease risk factors among persons with diabetes.
 ...
PMID:Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. 846 Jun 29

The effects of hyperglycemia (experimental diabetes) and insulin treatment were studied on cholesterol and total as well as individual components of phospholipids in red cell membrane from adult rats. While total phospholipid content did not change significantly, the individual components were selectively affected. Cholesterol content was reduced markedly during hyperglycemia. Insulin administration to hyperglycemic rats in general appeared to cause a reversal of the diabetic effects. A direct action of insulin on the red cell phospholipids and cholesterol metabolism was observed.
 ...
PMID:Changes in the lipid composition of red blood cells in hyperglycemic rats. 209 94

Diabetes is thought to be associated with alterations in biliary function involved in a higher prevalence of gallstones in diabetic patients. However, the presence of supersaturated bile in diabetes is still controversial. To gain information on this point, we studied the effect of insulin deficiency on biliary secretion of bile acid, phospholipid, and cholesterol in anesthetized rats. Diabetes was induced by streptozotocin injection (6 mg/100 gm body weight, intraperitoneally). Experiments were carried out at different times (from 1 to 28 days) after diabetes induction. Some rats received insulin (10.5 U/100 gm body weight; divided into five doses) from the third to the sixth day after administration of streptozotocin. Shortly after streptozotocin injection (1 day), bile acid output was decreased but later markedly increased (from 6 days). However, cholestasis was apparent in all insulin-deficient groups. Biliary lecithin concentrations and secretion rate were enhanced from the first day of diabetes. Moreover, an increase in the biliary percentage of lecithin (from 53% to 71% of total biliary phospholipid), which was counterbalanced mainly by a decrease in the biliary concentration of phosphatidylethanolamine, was observed in rats with diabetes for 6 days. Cholesterol concentrations in bile were also higher in diabetic rats. However, the lithogenic index (i.e., percent of cholesterol saturation) was never higher than in healthy rats (55.7%). Cholesterol output induced by taurocholate infusion was not significantly different in control and in 6-days diabetic rats. Nevertheless, biliary lecithin secretion stimulated by taurocholate infusion was markedly increased (the number of lecithin molecules accompanying every 100 molecules of bile acid into bile was 7 and 18 in control and diabetic rats, respectively, at bile acid rates lower than 150 nmol/min per gram liver). Administration of insulin to diabetic rats reversed the above-reported changes. These results indicate that streptozotocin induces profound changes in the mechanisms responsible for bile acid-induced biliary lipid secretion, which are due to the insulin deficiency rather than to a direct hepatotoxic effect of the diabetogenic drug.
 ...
PMID:Enhancement of bile acid-induced biliary lipid secretion by streptozotocin in rats: role of insulin deficiency. 213 93

Coronary heart disease is the leading cause of death among patients with non-insulin-dependent diabetes mellitus (NIDDM). NIDDM patients have a high frequency of dyslipidemia, which along with obesity, hypertension, and hyperglycemia may contribute significantly to accelerated coronary atherosclerosis. Because risk factors for coronary heart disease are additive and perhaps multiplicative, even mild degrees of dyslipidemia may enhance coronary heart disease risk. Therefore, therapeutic strategies for management of NIDDM should give equal emphasis to controlling hyperglycemia and dyslipidemia. The National Cholesterol Education Program recently issued guidelines for treatment of hyperlipidemia in adults including diabetic patients. Because of the unique features of diabetic dyslipidemia, however, we suggest that certain modifications in these guidelines be made to meet specific needs of diabetic patients. For example, therapeutic goals for serum cholesterol reduction should be lower in diabetic patients than in nondiabetic subjects. Particular emphasis should be given to weight reduction in NIDDM patients. In some diabetic patients, monounsaturated fatty acids may be a better replacement for saturated fatty acids than carbohydrates. The target for cholesterol lowering should include both very-low-density lipoprotein and low-density lipoprotein (LDL) (non-high-density lipoprotein) rather than LDL alone. To obtain a substantial reduction of cholesterol levels, drug therapy may be required in many patients. However, first-line drugs for nondiabetic patients (nicotinic acid and bile acid sequestrants) may be less desirable in NIDDM patients than hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors and even fibric acids. In fact, HMG CoA reductase inhibitors may be the drugs of choice for NIDDM patients with elevated LDL cholesterol and borderline hypertriglyceridemia, whereas gemfibrozil appears preferable for NIDDM patients with severe hypertriglyceridemia.
Diabetes Care 1990 Feb
PMID:Management of dyslipidemia in NIDDM. 219 Jul 70

Screening for dyslipoproteinemias should be undertaken in all individuals older than 20 years of age at least once every 5 years. The initial screening, as recommended by the Adult Treatment Guidelines Panel of the National Cholesterol Education Program, is to determine the concentration of total blood cholesterol. This initial determination can be made on blood obtained in the nonfasting state. Further evaluation of the patient's lipoprotein concentrations is dependent upon the presence of other cardiovascular risk factors. in the absence of definite coronary heart disease, hypertension, diabetes mellitus, a family history of coronary artery disease, cigarette smoking, or severe obesity, the patient with a total blood cholesterol concentration less than 200 mg/dL requires no specific instruction and should have a repeated screening performed within 5 years. Patients with blood cholesterol concentrations greater than 200 mg/dL should have their lipoprotein profiles determined if they have atherosclerotic cardiovascular disease or two other cardiovascular disease risk factors. The lipoprotein profile includes the determination of fasting cholesterol and triglyceride and HDL cholesterol concentrations. From these values, the LDL cholesterol concentration can be calculated. This LDL cholesterol concentration is central in selecting the appropriate therapy. HDL cholesterol concentrations may be useful in evaluating patients with ischemic heart disease. Concentrations of HDL cholesterol less than 35 mg/dL are associated with increased risk for coronary artery disease. Although there is currently no convincing evidence that support the specific treatment of depressed HDL cholesterol concentrations, therapy directed to modulating lipoprotein metabolism in patients with heart disease and low HDL concentrations may be of benefit. Patients with recurrent abdominal pain, pancreatitis, and eruptive xanthomatosis frequently have fasting hypertriglyceridemia concentrations exceeding 1000 mg/dL. These patients should be identified in order to effectively reduce their triglyceride concentrations, which can prevent these complications.
 ...
PMID:Detection and evaluation of dyslipoproteinemia. 219 76

A small rural Aboriginal community in northern Australia was surveyed for diabetes, impaired glucose tolerance (IGT), hyperinsulinemia, and lipid levels. Of the 122 adults greater than 17 yr of age who participated (95% response rate), 11.5% had diabetes, 7.4% had IGT, and the remaining 81.1% had normal glucose tolerance. Both diabetes and IGT were strongly age related. This high frequency of diabetes occurred, despite the population being relatively lean. Although the body mass index (BMI) increased with age in both men and women, only 25% of the population overall had BMI greater than 25 kg/m2. There were wide ranges of insulin responses to glucose, with the upper tertile of 2-h insulin levels being more than seven times higher than the lower tertile (144 +/- 13 vs. 19 +/- 1 mU/L). Hyperinsulinemia was associated with IGT, elevated triglycerides, and lower high-density lipoprotein cholesterol levels. Lipid abnormalities were much more frequent among men than women. Cholesterol levels were an average of 0.55 mM higher and triglycerides an average of 1.05 mM higher in men than in women, and both increased with age. In conclusion, this small isolated Aboriginal population from northern Australia had an unexpectedly high frequency of diabetes (in view of their relative leanness) in association with a high frequency of metabolic abnormalities indicative of insulin resistance (hyperinsulinemia, IGT, hypertriglyceridemia).
Diabetes Care 1990 Aug
PMID:Diabetes, hyperinsulinemia, and hyperlipidemia in small aboriginal community in northern Australia. 220 16

Lipid and apolipoprotein (apo) levels were investigated in 98 (68 female, 30 male) subjects older than 85 years and 86 (59 female, 27 male) subjects aged 65-75 years. The mean cholesterol level of the long-lived persons who were free from overt degenerative arterial disease was 5.2 mmol/l and ranged markedly below the mean level of the population. Comparing both age groups, the triglyceride level of the high-age subjects was at 0.3 mmol/l, significantly lower; HDL-cholesterol and apo A-I at 0.15 mmol/l or 0.3 g/l were higher. Cholesterol, LDL-cholesterol, and apo B only tended to be lower in the higher age. Subjects suffering from degenerative arterial disease (circulatory disturbance, hypertonia, diabetes mellitus), especially the long-lived group, had a more marked unfavorable lipoprotein profile. Subjects over 85 years (13%) had markedly less disturbance in lipoprotein metabolism of high atherogenic potency (hyper-beta-, hypo-alpha-lipoproteinemia) than did subjects 65-75 years old (23%). Hypertriglyceridemia is with 38% or rather 21% very frequent and seems to be of less atherogenic potency. Hyper-alpha-lipoproteinemia as anti-risk factor for coronary heart diseases was established more frequently in the long-lived group with 13% in comparison to 3.5% in those 65-75 years of age.
 ...
PMID:[Lipoproteins as coronary risk or non-risk indicators in elderly people]. 229 2

The National Cholesterol Education Program treatment guidelines define a plasma total cholesterol of less than 200 mg/dl as "desirable" and recommend no further evaluation of plasma lipid or lipoprotein levels in patients with coronary artery disease (CAD). To determine the prevalence of dyslipidemias in the presence of coexistent CAD and total cholesterol less than or equal to 200 mg/dl, a retrospective case-control study of 1,000 patients who underwent diagnostic coronary angiography was performed. Of 351 patients with total cholesterol less than or equal to 200 mg/dl, 76% of the men (244) and 44% of the women (107) had angiographically demonstrated CAD. In men with CAD and total cholesterol less than or equal to 200 mg/dl, there was a significantly greater prevalence of low levels of high density lipoprotein (HDL) cholesterol (less than or equal to 35 mg/dl), age greater than 50 years, systemic hypertension and diabetes mellitus compared to non-CAD control subjects. In women with CAD and total cholesterol less than or equal to 200 mg/dl, HDL cholesterol less than or equal to 45 mg/dl and diabetes mellitus were also significantly prevalent. Multiple logistic regression analyses revealed that HDL cholesterol, hypertension and age in men and very low density lipoprotein cholesterol in women were significantly associated with CAD after adjustment for other risk factors. These results suggest that a complete lipid and lipoprotein analysis be obtained in all patients with CAD, irrespective of the plasma (or serum) total cholesterol level.
 ...
PMID:Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. 229 75

Diabetes mellitus is often associated with lipid abnormalities that may differ with sex. In this work we studied biliary lipid secretion in male and female anaesthetized Wistar rats (250 g). Diabetes was induced by a single intraperitoneal injection of streptozotocin (6 mg/100 body weight) 6 days before carrying out the studies on bile secretion. Our results confirm the existence of sex differences in bile formation and composition, most of them probably due to a higher (+27%) bile acid output in the female animals. Diabetes induced profound alterations in these sex differences. (a) Bile flow was reduced in both sexes, but more markedly so in female diabetic rats; thus the difference observed in healthy animals was reduced (from 2.22 to 1.58 and from 1.84 to 1.40 microliters/min per g liver in female and male rats, respectively). (b) Bile acid and phosphatidylcholine outputs were increased to a similar extent (bile acid output: from 46.7 to 55.8 nmol/min per g liver, in females and from 36.8 to 50.7 nmol/min per g liver, in males; phosphatidylcholine output: from 3.3 to 13.1 nmol/min per g liver, in females and from 4.5 to 12.5 nmol/min per g liver, in males), and hence the sex differences were abolished. (c) Cholesterol output was increased in both sexes, but this enhancement was significantly higher in female rats (from 0.75 to 1.31 and from 0.65 to 0.89 nmol/min per g liver, in females and males, respectively). (d) The fractional pool of phospholipid species secreted into bile was different in female compared with male rats. The percentage of phosphatidylcholine was higher in female than in male healthy rats. Streptozotocin treatment reversed this proportion, which suggests that changes in the phospholipid composition of the canalicular plasma membrane may play a role in the observed alterations in biliary lipid secretion during diabetes mellitus. Most of the above-described streptozotocin-induced changes were prevented by insulin replacement from the 3rd to the 6th days after streptozotocin injection. In summary, the present study describes alterations in sex differences in biliary lipid secretion of streptozotocin-induced diabetes. These changes are dependent on the insulin deficiency state rather than on a direct hepatotoxicity of the diabetogenic drug.
 ...
PMID:Effect of streptozotocin-induced diabetes on sex differences in biliary lipid secretion in the rat. 231 Jul 55


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>